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Abstract: Allergic rhinitis is a very common disease affecting about 20% of people. It may 
be treated by allergen avoidance when possible, by antiallergic drugs such as antihistamines 
and topical corticosteroids, and by allergen-specific immunotherapy. The latter is the only 
treatment able to act on the causes and not only on the symptoms of respiratory allergy and is 
able to maintain its efficacy even after stopping, provided an adequate duration of treatment 
of 3–5 years is ensured. Sublingual immunotherapy (SLIT) was introduced in the 1990s as a 
possible solution to the problem of adverse systemic reactions to subcutaneous immunotherapy 
and has been demonstrated by more than 50 trials and globally evaluated thus far by five meta-
analyses as an effective and safe treatment for allergic rhinitis. Life-threatening reactions are 
extremely rare. However, it is important to note that clinical efficacy occurs only if SLIT meets 
its needs, ie, sufficiently high doses are regularly administered for at least 3 consecutive years. 
This is often overlooked in the current practice and may prevent the same success reported by 
trials from being achieved.
Keywords: allergic rhinitis, sublingual immunotherapy, efficacy, safety, compliance, 
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Introduction
Allergic rhinitis (AR) is a very common disease with a high and still increasing 
world prevalence.1 AR causes an important medical and social burden,2 which further 
increases when the disease is associated with allergic asthma.3 In fact, the concurrence 
of AR and asthma requires more doctor visits and more drugs and worsens patients’ 
quality of life.4
The management of respiratory allergy relies on, when possible, allergen avoidance, 
drug treatment, and allergen-specific immunotherapy (SIT).3 SIT is the practice of 
administering gradually increasing doses of the specific causative allergen to reduce the 
clinical reactivity of allergic subjects. This treatment has pivotal importance because 
of its ability to modify the natural history of the disease and to extend its effectiveness 
after treatment withdrawal, provided it is administered with sufficiently hgh doses and 
for an adequate duration.5 Subcutaneous immunotherapy (SCIT) has for decades been 
the traditional technique of administration, but it is flawed by the problem of adverse 
systemic reactions, which, when they are of an anaphylactic type, may be severe and, 
though very rarely, even fatal.6 In recent years, sublingual immunotherapy (SLIT) has 
emerged as an actual treatment option because of its clinical efficacy and safety.7
The first studies on SLIT used low allergen dosages,8,9 but it soon became apparent 
that doses much higher than those administered by SCIT were needed to expect clinical Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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efficacy. In consensus documents, an optimal dose as high 
as at least 50 times the dose administered by injection was 
suggested.3 The high number of trials on SLIT conducted 
in recent years allows an accurate evidence-based assess-
ment of its efficacy based on several meta-analyses, and the 
most recent data also give an indication on optimal doses 
to be used.
This review aims to analyze the current role of SLIT in 
the treatment of AR using evidence-based demonstrations 
of its efficacy and safety.
Search strategy and study selection
The medical literature was searched by means of the MedLine 
database for the years 1990–2010 using the following key 
words: “sublingual immunotherapy”, “efficacy”, “safety”, 
“tolerability”, “compliance”, “meta-analysis”, and “system-
atic review”. The search was augmented by scanning the 
references cited in the articles identified. Only full-length 
articles in English that had been published in referenced 
journals were considered. Full copies of the articles were 
retrieved for analysis and the relevant data were extracted.
Analysis of efficacy of SLIT
The clinical efficacy of SLIT in AR, as for SIT in general, 
can be evaluated by a decrease in symptom scores of rhinitis 
and in the use of symptomatic drugs. Most of the placebo-
controlled studies usually include small patient populations 
and thus are exposed to the issue of not having fully reliable 
statistical significance. An adequate statistical method to 
achieve statistical reliability is meta-analysis that estimates 
more powerfully the effect size of a medical treatment by 
combining the results of several trials and expresses the 
results as standardized mean difference (SMD), comparing 
the effect of active and placebo treatment on patients. The 
results from the meta-analyses on SLIT in AR are summa-
rized in Table 1.
In 2005, when 22 randomized controlled trials (RCTs) 
were available, Wilson et al published the first meta-analysis 
on SLIT,10 which demonstrated a significantly higher efficacy 
of SLIT versus placebo, with an SMD corresponding to -0.42 
for symptom scores (P = 0.002) and to -0.43 for medication 
scores (P = 0.00003). In the same year, another meta-analysis 
dealt with seven RCTs conducted on children aged up to 
14 years and found that SLIT was significantly effective on 
asthma symptoms (SMD -1.42; P = 0.01) and on drug con-
sumption (SMD -1.01; P = 0.06), but the improvement did 
not reach significance for nasal and eye symptoms.11
However, a further meta-analysis on SLIT in children, 
concerning only efficacy on AR, showed positive results.12 
Ten RCTs with an overall number of 484 patients 
(245 actively treated and 239 placebo treated) were 
included, and a significant reduction of both symptoms 
(SMD -0.56, P = 0.02) and medication scores (SMD -0.76, 
P = 0.03) was found. Of note, the subanalysis addressing the 
length of treatment and the kind of allergen administered 
demonstrated a higher efficacy for durations longer than 
18 months and for pollen allergens compared with house 
dust mites.
The most recent meta-analyses highlighted the results 
according to the allergen used for SLIT. Compalati et al 
examined eight RCTs for AR (including 194 adults and 
children).13 A significant reduction in symptoms of AR 
(SMD -0.95; P = 0.02) and a significant decrease in antial-
lergic medication use (SMD -1.88; P = 0.04) in SLIT-treated 
patients compared with placebo was found. Di Bona et al per-
formed a meta-analysis on RCTs conducted with grass pollen 
extracts, concluding that SLIT significantly reduces both 
symptoms (SMD -0.32) and medication use (SMD -0.33) 
compared with placebo, that it is more efficacious in adults 
than in children, and that prolonging the duration of pre-
seasonal treatment for more than 12 weeks improves treat-
ment efficacy.14
A recognized limit of meta-analysis is the usually relevant 
heterogeneity of the included studies, due to the different 
dosages, standardization methods, treatment schedules, 
and patient populations. Recent evaluations considered the 
available meta-analyses altogether but reached contrasting 
conclusions. Nieto et al checked the data reported in the 
Table 1 Summary results from meta-analyses on sublingual immunotherapy in allergic rhinitis
Study Population  Number of patients Allergen used Standardized  
mean difference
wilson et al10 Adults and children 979 (503 active, 476 placebo)  various -0.42
Olaguibel et al11 Children  256 (129 active, 127 placebo) various -0.44
Penagos et al12 Children 484 (245 active, 239 placebo) various -0.56
Compalati et al13 Adults and children 382 (194 active, 188 placebo) House dust mite -0.95
Di Bona et al14 Adults and children 2971 (1518 active, 1453 placebo) Grass pollen -0.32Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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original studies and concluded that the meta-analyses show 
“discrepancies, inconsistencies, and lack of robustness” 
and “do not provide enough evidence” for the current 
routine use of SLIT in patients with allergic asthma or 
rhinoconjunctivitis.15 By contrast, the overall evaluation 
of all meta-analyses (five on SLIT and two on SCIT) by 
  Compalati et al, despite a significant heterogeneity of studies 
and one negative meta-analysis, led the authors to conclude 
that “SIT can be recommended for the treatment of respira-
tory allergy because of its efficacy in reducing asthma and 
rhinitis symptoms”.16
The limit of heterogeneity can be overcome by analyzing 
single studies conducted on large numbers of patients that 
allow adequate statistical power. The recent preparations 
for SLIT in tablets of grass pollen extract were evaluated on 
large populations, including 855 adults treated by a Timothy 
grass extract,17 628 adults treated using a five-grass pollen 
extract,18 and 278 children treated using the same five-grass 
preparation.19 These studies showed a highly significant 
improvement in symptoms and rescue medication scores 
in actively treated compared with placebo-treated patients 
during the grass pollen season.
Important observations from such studies concern the 
dose dependence of clinical efficacy: only high doses, 
corresponding to 75,000 SQ in the trial with the Timothy 
grass pollen17 and to 300 IR in the trial with the five-grass 
extract,18 were effective. These doses correspond to 15 mcg 
and 20 mcg of the major allergens Phl p 5, respectively. 
Calculating the monthly cumulative dose, the World Allergy 
Organization Position Paper on SLIT suggested the monthly 
dose of 600 mcg of the grass pollen major allergen Phl p 5 as 
being optimal.20 This is confirmed by the meta-analysis on 
grass pollen SLIT by Di Bona et al, showing clearly better 
results (SMD -0.47) in patients receiving monthly doses of 
275–600 mcg than in patients receiving monthly doses lower 
than 275 mcg (SMD -0.16).14
Another important aspect of SLIT efficacy is the identi-
fication of patients more prone to respond to the treatment. 
Devillier et al21 performed a post hoc analysis of data from 
the registrative studies with the new grass pollen tablets for 
SLIT.18,19 From such analysis it was apparent that the mag-
nitude of efficacy was higher in patients with more severe 
symptoms during the grass pollen season. In fact, for the adult 
trial, the differences of the symptom–medication score in the 
active versus placebo groups were 15%, 26%, and 37% for 
the low-, moderate-, and high-severity tertiles, respectively; 
in the pediatric trial, these values were 10%, 33%, and 34%, 
respectively.21
Analysis of safety and tolerability  
of SLIT
The meta-analyses including, along with efficacy, the safety 
and tolerability aspects of SLIT found that the most common 
adverse events were local reactions in the oropharynx 
followed by gastrointestinal reactions (such as vomiting and 
diarrhea) and that systemic reactions such as asthma, rhinitis, 
or urticaria were quite rare.10,13
Specific reviews on safety are also available that address 
only children22,23 or patients of any age.24,25 Of note, differ-
ently from SCIT, there was not a dose dependence of safety, 
as the rate of systemic reactions was similar in studies using 
low doses and in studies using high doses.24 In a subsequent 
trial evaluating seven groups of patients treated with increas-
ing doses, the treatment-related adverse events, including 
irritation of the throat, and itching sensations in the mouth 
and ears, increased with dose.26 In fact, local reactions are 
generally estimated to concern 20%–40% of patients, but they 
can be easily managed and usually do not result in treatment 
withdrawal.27 Anaphylactic reactions are extremely rare; 
a review of published reports showed that in most cases the 
reaction is associated with mistakes, such as the use of an 
improper mix of allergens or the consumption of very high 
allergen doses.28 However, an increased risk is apparent in 
subjects undergoing SLIT because of previous systemic reac-
tions to SCIT,29,30 especially when no updosing regimens are 
used. This warrants reconsideration of systemic reactions to 
SCIT as an admission criterion to SLIT.31 In any case, starting 
directly with the maintenance dose is not recommended in any 
patient, regardless of previous reactions to IT. In fact, a Phase I 
study comparing different doses and different updosing or no 
updosing regimens showed that only the group of patients 
treated with the highest dose with no updosing had severe 
local reactions with swelling of throat.32
Analysis of compliance with SLIT
Based on the available studies, the major cause of non-
compliance with SLIT is inconvenience due to visits to 
allergists’ offices for the injections.33 SLIT has different 
compliance issues from SCIT, because it is administered 
at home by patients themselves, and thus should have com-
pliance problems similar to drug treatment. However, the 
findings from studies specifically designed for compliance 
and adherence indicate quite satisfactory results, with values 
between 75% and 95% of treated subjects.33 In a survey on 
allergists’ opinions on the factors positively influencing 
adherence to SLIT, the issues judged to be most important 
were the patient’s perception of efficacy, reimbursability, Journal of Asthma and Allergy 2011:4 submit your manuscript | www.dovepress.com
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and   tolerability and the patient’s education.34 Concerning 
  perception of efficacy, as previously noted in SCIT studies, 
it was observed that a lack of compliance to SLIT may be 
caused by the erroneous perception that once allergic symp-
toms are improved, SLIT is no longer needed.35 However, this 
aspect also belongs to the field of patient education, which 
has pivotal importance, as shown in a recent study that found 
a clear difference in compliance between patients receiving 
a complete educational course on SLIT and those receiving 
only standard instructions.36
Analysis of the carryover  
effect of SLIT
A major advantage of SCIT over drug treatment is that efficacy 
on allergic symptoms persists after its discontinuation.5 Recent 
studies showed that SLIT also has such a carryover effect. In 
a survey on SLIT using a dust mite extract, 137 patients were 
divided into two groups, 67 receiving SLIT for 2 years and 70 
receiving SLIT for 3 years. All patients were followed up for 
3 years after stopping the treatment. A greater improvement 
of symptoms was found in the patients treated for 3 years.37 In 
a prospective open controlled study, patients monosensitized 
to mites were divided into four groups, one receiving only 
drug treatment and the other three receiving SLIT for 3, 4, 
or 5 years. The observation period reached 15 years, and the 
clinical scores showed that the benefit persisted for 7 years 
in patients treated for 3 years, whereas the benefit persisted 
for 8 years in those treated for 4–5 years.38 Moreover, new 
allergen sensitizations occurred in all patients treated only 
with drugs and in less than 25% of patients receiving SLIT.
Conclusion
SLIT has gained ample evidence of efficacy and safety and in 
some European countries is currently used more frequently 
than SCIT. Apart from its better safety profile, the advantages 
of SLIT over SCIT are with regard to compliance, which is 
higher because SLIT does not need to be administered in a 
medical setting, and cost-effectiveness, because the cost of 
the injections is not involved.39 However, it is important to 
note that such favorable outcomes exist only if SLIT meets its 
needs, ie, the administration of high doses is continued regu-
larly for at least 3 consecutive years. In fact, SLIT efficacy is 
dose dependent, and a sufficient duration of treatment is nec-
essary to induce the immunologic changes underlying clinical 
effectiveness. Recent studies showed that the mechanism of 
action of SLIT is similar to that demonstrated for SCIT,40 
and that when high doses are administered, immunoglobulin 
G-blocking antibodies, which were not found in SLIT studies 
employing low doses, are produced in significant amounts 
and persist after the discontinuation of treatment.41
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